Last reviewed · How we verify
TetraLens bandage contact lens
TetraLens bandage contact lens is a Small molecule drug developed by Vance Thompson Vision. It is currently in Phase 1 development.
At a glance
| Generic name | TetraLens bandage contact lens |
|---|---|
| Sponsor | Vance Thompson Vision |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the TetraLens, a Tetracaine Releasing Therapeutic Bandage Contact Lens in Patients Undergoing PRK Procedure (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TetraLens bandage contact lens CI brief — competitive landscape report
- TetraLens bandage contact lens updates RSS · CI watch RSS
- Vance Thompson Vision portfolio CI
Frequently asked questions about TetraLens bandage contact lens
What is TetraLens bandage contact lens?
TetraLens bandage contact lens is a Small molecule drug developed by Vance Thompson Vision.
Who makes TetraLens bandage contact lens?
TetraLens bandage contact lens is developed by Vance Thompson Vision (see full Vance Thompson Vision pipeline at /company/vance-thompson-vision).
What development phase is TetraLens bandage contact lens in?
TetraLens bandage contact lens is in Phase 1.